Loading…
SCYNEXIS, Inc. is projected to rise to $4.75 by 2027, a +4% move from its current price of $4.57. SCYX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $4.41 | $4.57 | $4.73 | +0.02% |
| Jul 13 | $4.35 | $4.57 | $4.79 | +0.04% |
| Jul 14 | $4.30 | $4.57 | $4.85 | +0.06% |
| Jul 15 | $4.27 | $4.57 | $4.89 | +0.08% |
| Jul 16 | $4.23 | $4.57 | $4.93 | +0.10% |
| Jul 17 | $4.20 | $4.57 | $4.97 | +0.12% |
| Jul 18 | $4.17 | $4.57 | $5.01 | +0.14% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.17 | $4.57 | $5.01 | +0.14% |
| Week 2 | $4.03 | $4.58 | $5.20 | +0.28% |
| Week 3 | $3.92 | $4.58 | $5.36 | +0.42% |
| Week 4 | $3.83 | $4.59 | $5.50 | +0.56% |
| Week 5 | $3.75 | $4.60 | $5.63 | +0.70% |
| Week 6 | $3.69 | $4.60 | $5.75 | +0.84% |
| Week 7 | $3.63 | $4.61 | $5.86 | +0.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
SCYNEXIS, Inc. is a biotechnology company focused on drug development for difficult-to-treat and drug-resistant fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis and to reduce recurrence, and it also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections.
The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYNEXIS operates in the healthcare sector with a pipeline centered on antifungal therapies. Its product-focused approach targets infections that can be challenging to treat, reflecting its niche within biotechnology and infectious-disease drug development.
The company’s name and corporate history are noted in the provided background, including its long-standing presence as a Jersey City–based biotech entity since 1999. This framing emphasizes its focus on therapeutic development and its US-centric scope.
SCYNEXIS, Inc. (SCYX) is trading at $4.73 per share. It holds a market capitalization of $46.97M and ranks 4533 by market cap.
The current price sits within a broader forecast that envisions a path of modest near-term activity and more sustained upside into the 2030s and beyond, with average prices advancing from the mid-2020s through 2030 and beyond. The latest numbers show an average price around current levels in the near term, followed by higher projected averages in later years.
In the multi-year view, the forecast projects positive returns beginning later in the decade with notable upside in the 2040s and 2050s. The implied ROI grows from single-digit levels in the near term to triple-digit magnitudes by 2050, reflecting a bullish longer-term stance alongside continued development of the antifungal franchise.
A major floor 85.6% below — a decisive break under it would weaken the trend.
The nearest floor, 16.8% below — buyers have tended to step in here.
The nearest ceiling, 28.8% above — a clean break opens room to run.
A major ceiling 85.9% above — clearing it would confirm fresh momentum.
Key SCYX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SCYX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.59 | Sell | $4.48 | Buy |
| MA 10 | $4.34 | Buy | $4.38 | Buy |
| MA 20 | $4.16 | Buy | $4.12 | Buy |
| MA 50 | $2.87 | Buy | $3.23 | Buy |
| MA 100 | $1.88 | Buy | $2.37 | Buy |
| MA 200 | $1.30 | Buy | $1.73 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.47 | Neutral |
| Stoch RSI (14) | 17.98 | Buy |
| CCI (20) | 55.07 | Neutral |
| Williams %R (14) | -37.63 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 14.66 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 62.37 | Neutral |
| TRIX (15) | 1.95 | Buy |
| Awesome (5,34) | 0.77 | Buy |
| Ultimate (7,14,28) | 58.33 | Neutral |
| Momentum (10) | 0.57 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 4.67 | Sell |
| ADX (14) | 30.65 | Buy |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is neutral, with RSI14 at 50, suggesting neither overbought nor oversold conditions.
Moving averages show the stock trading below the SMA50 of $5.55 and the SMA200 of $6.04, indicating potential resistance above the current price. The immediate resistance is $5.88 and the nearest support is at $3.80.
Over the last 30 days, the price has traded in a range from $3.71 to $6.03, illustrating the sensitivity to short-term momentum and providing a defined boundary for near-term movement.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.80 | $4.57 | $6.29 | 0% | Neutral | |
| $3.69 | $4.75 | $6.52 | +4% | Neutral | |
| $3.59 | $4.79 | $6.87 | +5% | Neutral | |
| $3.38 | $4.64 | $6.90 | +2% | Neutral | |
| $3.36 | $4.74 | $7.26 | +4% | Neutral | |
| $3.90 | $5.65 | $8.86 | +24% | Bullish | |
| $4.14 | $6.13 | $9.84 | +34% | Bullish | |
| $4.52 | $6.84 | $11.20 | +50% | Bullish | |
| $4.75 | $7.33 | $12.24 | +61% | Bullish | |
| $4.09 | $6.44 | $10.93 | +41% | Bullish | |
| $5.71 | $9.86 | $17.99 | +116% | Bullish | |
| $7.44 | $15.12 | $30.62 | +231% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $3.80 | $4.57 | $5.55 | +0.00% |
| August 2026 | $3.83 | $4.55 | $5.58 | -0.32% |
| September 2026 | $3.88 | $4.65 | $5.78 | +2.17% |
| October 2026 | $4.08 | $4.93 | $6.20 | +6.08% |
| November 2026 | $4.11 | $4.99 | $6.34 | +1.26% |
| December 2026 | $4.02 | $4.91 | $6.29 | -1.59% |
Click any year to see its month-by-month SCYX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SCYX is projected to trade between $3.80 and $6.29, averaging $4.57 — a potential gain of 0% from today's $4.57. Price action looks broadly range-bound.
SCYNEXIS, Inc.'s 2027 outlook centres on $4.75, within a $3.69 to $6.52 range. That is up +4% on the projected 2026 average. That marks a +4% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, SCYX could reach as high as $6.87, with a base case around $4.79 and support toward $3.59 — roughly +5% from $4.57. Price action looks broadly range-bound.
Expect SCYX to range from $3.38 to $6.90 through 2029. The $4.64 average target implies a +2% move from current prices. That is -3% versus the projected 2028 average. A consolidation phase looks the most probable path here.
The SCYX price prediction for 2030 points to an average of $4.74 (low $3.36, high $7.26) — a potential gain of +4% on today's $4.57. Price action looks broadly range-bound.
In 2031, SCYX is projected to trade between $3.90 and $8.86, averaging $5.65 — a potential gain of +24% from today's $4.57. That is up +19% on the projected 2030 average. Buyers look set to stay in control over this stretch.
SCYNEXIS, Inc.'s 2032 outlook centres on $6.13, within a $4.14 to $9.84 range. That is up +9% on the projected 2031 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2033, SCYX could reach as high as $11.20, with a base case around $6.84 and support toward $4.52 — roughly +50% from $4.57. Buyers look set to stay in control over this stretch.
Expect SCYX to range from $4.75 to $12.24 through 2034. The $7.33 average target implies a +61% move from current prices. That is up +7% on the projected 2033 average. Momentum favours further upside here.
The SCYX price prediction for 2035 points to an average of $6.44 (low $4.09, high $10.93) — a potential gain of +41% on today's $4.57. Buyers look set to stay in control over this stretch.
In 2040, SCYX is projected to trade between $5.71 and $17.99, averaging $9.86 — a potential gain of +116% from today's $4.57. That is up +53% on the projected 2035 average. Momentum favours further upside here.
SCYNEXIS, Inc.'s 2050 outlook centres on $15.12, within a $7.44 to $30.62 range. That is up +53% on the projected 2040 average. That marks a +231% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in SCYX today (≈ 219.05805 SCYX) could be worth
$3,312.92
+$2,312.92 (+231%) by 2050 · US Dollar
Based on the average projected SCYX price of $15.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SCYXwould be worth at today's price.
$1,000 invested in SCYX on Jul 10, 2025 (≈ 1,428.571453 SCYX) would be worth
$6,521.43
+$5,521.43 (+552.1%) today · 6.52× · US Dollar
Based on a SCYX entry price of $0.7 vs. today's $4.57.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.43 | $1,030.47 | +3.0% |
| 1 month ago | $4.15 | $1,100 | +10.0% |
| 3 months ago | $1 | $4,565 | +356.5% |
| 6 months ago | $0.656 | $6,958.84 | +595.9% |
| 1 year ago | $0.7 | $6,521.43 | +552.1% |
| All time (5.0y) ago | $7.33 | $622.78 | -37.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SCYX forecast.
Our base-case forecast reaches $9.10 around 2040.
Implied market cap at $9.10: $90.37M
The year-by-year outlook shows a gradual rise in average prices across the forecast, with notable milestones. In 2026 the average is projected at $4.73 with a min of $3.80 and a max of $6.60, and a 0% ROI, reflecting neutral sentiment.
By 2030, the average is seen at $4.93 with a min of $3.43 and a max of $7.68, and a 4.2% ROI, still labeled neutral but indicating modest upside potential.
From 2031 onward the trajectory strengthens: 2031 avg $5.89 (ROI 24.6, bullish), 2032 avg $6.46 (ROI 36.6, bullish), 2033 avg $7.24 (ROI 53.1, bullish), and 2034 avg $7.71 (ROI 62.9, bullish). The forecast continues to 2035 with avg $6.70 (ROI 41.6, bullish).
Towards the end of the forecast horizon, 2040 shows a strong rise to an average of $10.41 (ROI 120, bullish), and 2050 projects an average of $15.98 (ROI 237.9, bullish). These figures illustrate a clear long-term upside while acknowledging the inherent uncertainty of biotech investments.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.93 with a min of $3.43 and a max of $7.68, and an ROI of 4.2%. The sentiment is Neutral.
Near-term numbers show a neutral stance with 2026 average at $4.73 and 0% ROI. The forecast turns bullish from 2031 onward, with 2031 average $5.89 and ROI 24.6%, and continues to rise to 2040 average of $10.41 (ROI 120) and 2050 average of $15.98 (ROI 237.9%), indicating potential upside over the longer horizon, though these are estimates, not guarantees.
Yes. The forecast shows higher-price opportunities, with 2032 max $10.59 and 2033 max $12.13. The 2040 max is $19.53 and the 2050 max is $33.42, indicating potential to exceed $10 under the projected path.
In 2040 the average is projected at $10.41 (ROI 120), and in 2050 the average is projected at $15.98 (ROI 237.9). The bullish sentiment persists through 2031–2050, reflecting a potential long-term upside against the near-term neutral backdrop.
The current price is $4.73 per share, with a market capitalization of $46.97M and a rank of 4533.
SCYNEXIS, Inc. Community Discussion
0Share your SCYNEXIS, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.